Overview

A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

Status:
Active, not recruiting

Trial end date:
2021-11-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of givosiran (ALN-AS1) in AIP patients

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Alnylam Pharmaceuticals